<DOC>
	<DOCNO>NCT00138151</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Sometimes chemotherapy give , stop growth tumor cell . The tumor say resistant chemotherapy . Giving isotretinoin interferon alpha-2b together paclitaxel may reduce drug resistance allow tumor cell kill . PURPOSE : This phase II trial study well give isotretinoin interferon alpha-2b together paclitaxel work treat patient stage IV , recurrent , persistent cervical cancer .</brief_summary>
	<brief_title>Isotretinoin , Interferon Alpha-2b , Paclitaxel Stage IV , Recurrent , Persistent Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response patient stage IVB , recurrent , persistent cervical cancer treat isotretinoin , interferon alpha-2b , paclitaxel . OUTLINE : This multicenter study . Patients receive oral isotretinoin interferon alpha-2b subcutaneously daily day 1-4 paclitaxel IV 3 hour day 4 . Courses repeat every 21 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 27-66 patient accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically and/or cytologically confirm cervical cancer , meet 1 follow criterion : Stage IVB disease Recurrent disease Persistent disease Patients previously treat chemoradiotherapy initial therapy must demonstrate disease progression Measurable disease physical exam radiographic study Not amenable chemoradiotherapy surgery PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 02 Life expectancy At least 6 month Hematopoietic WBC ≥ 3,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic SGOT SGPT ≤ 2 time upper limit normal Bilirubin ≤ 1.5 mg/dL Renal Creatinine ≤ 1.5 mg/dL OR Creatinine clearance ≥ 50 mL/min Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known HIV positivity No active infection No medical condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy No prior interferon No concurrent immunotherapy Chemotherapy See Disease Characteristics At least 3 month since prior chemoradiotherapy ( 6 week patient experience disease progression completion initial chemoradiotherapy ) No prior chemotherapy Endocrine therapy No concurrent hormonal therapy cancer Radiotherapy See Disease Characteristics See Chemotherapy Recovered prior radiotherapy No concurrent radiotherapy Surgery Recovered prior surgery No concurrent surgery cancer Other No prior retinoids No concurrent anticancer therapy No concurrent experimental agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
</DOC>